611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Health Tip: Treating a Dog BiteVets With PTSD Face Higher Odds for Early Death From Multiple CausesFDA Expands Cystic Fibrosis Treatment Approval to Children Ages 6 to 12AHA News: Half of U.S. Adults Should Monitor Blood Pressure at Home, Study SaysWidely Prescribed Class of Meds Might Raise Dementia Risk9/11 Dust Linked to Prostate Cancer in First RespondersOcean Swimming Causes Skin Changes: StudyNew Drug Combats Leading Cause of DwarfismAHA News: What Migraine Sufferers Need to Know About Stroke RiskNorovirus Fears Stir Recall of Frozen BlackberriesFlying Insects in Hospitals Carry 'Superbug' GermsU.S. Cases of Infant Gut Illness Plummet After Vaccine IntroducedAHA News: This Faulty Gene May Help Predict Heart Muscle DiseaseCell Mapping Provides New Insights About AsthmaHealth Tip: Recognizing Balance DisordersThe Safer Way to Ease Post-Surgical PainLong Work Hours Tied to Higher Odds for StrokeSudden Death Can Occur Even in Well-Controlled EpilepsyStatins May Lower Risk of Stroke After Cancer RadiotherapyExperimental Drug Shows Early Promise Against Sickle Cell DiseaseFitness in Middle Age Cuts Men's Odds for COPD LaterVitamin D Supplements May Not Help Your HeartHow to Head Off a Pain in the NeckSprouts Supermarkets Recalls Frozen Spinach Due to Listeria FearsA-Fib Can Raise Dementia Risk, Even in Absence of StrokeAnother Climate Change Threat: More 'Flesh-Eating' Bacteria?Heading to Europe This Summer? Get Your Measles ShotAiling Heart Can Speed the Brain's Decline, Study FindsHealth Tip: Preventing GlaucomaHead Injuries Tied to Motorized Scooters Are Rising: StudyOverweight Kids Are at Risk for High Blood PressureHot Water Soak May Help Ease Poor Leg CirculationHealth Tip: Understanding RosaceaHealth Tip: Causes of Swollen Lymph NodesAHA News: Study Provides Rare Look at Stroke Risk, Survival Among American IndiansCDC Opens Emergency Operations Center for Congo Ebola OutbreakScared Safe: Pics of Sun's Damage to Face Boost Sunscreen UseNo Needle Prick: Laser-Based Test Hunts Stray Melanoma Cells in BloodBats Are Biggest Rabies Danger, CDC SaysEmgality Receives First FDA Approval for Treating Cluster HeadacheZerbaxa Approved for Hospital-Acquired Bacterial PneumoniaBlood From Previously Pregnant Women Is Safe for Donation: StudyStudy Refutes Notion That People on Warfarin Shouldn't Eat Leafy GreensCancer Survivors Predicted to Top 22 Million by 2030Your Guide to a Healthier Home for Better Asthma ControlHigh Blood Pressure at Doctor's Office May Be More Dangerous Than SuspectedAHA News: 3 Simple Steps Could Save 94 Million Lives WorldwideHealth Tip: Dealing With Motion SicknessHealth Tip: Symptoms of MeningitisRace Affects Life Expectancy in Major U.S. Cities
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

First Drug Approved for Rare Eye Disease

HealthDay News
by -- Scott Roberts
Updated: Aug 23rd 2018

THURSDAY, Aug. 23, 2018 (HealthDay News) -- Oxervate (cenegermin) has been approved by the U.S. Food and Drug Administration to treat neurotrophic keratitis, a rare disease of the eye's cornea.

The cornea is the clear layer that covers the colored portion at the front of the eye.

Neurotrophic keratitis affects fewer than five in 10,000 people, the FDA said. The disease, causing loss of corneal sensation, leads to damage of this vital part of the eye.

"While the prevalence of neurotrophic keratitis is low, the impact of this serious condition on an individual patient can be devastating," Dr. Wiley Chambers, an ophthalmologist in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

Oxervate, produced as an eyedrop, was evaluated in a clinical study involving 151 people with neurotrophic keratitis. Some participants were given Oxervate, while others were given a placebo eye drop. Complete corneal healing was reported among 70 percent of people treated with Oxervate, compared with 28 percent of those given the placebo, the FDA said.

The most common side effects of the drug included eye pain, enlarged blood vessels in the eye, eye inflammation and watery eyes.

Oxervate is produced by the Italian firm Dompé farmaceutici.

More information

Visit the FDA to learn more.